Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus [3]

Clinical Infectious Diseases

Volumn 33, Issue 3, 2001, Pages 414-415

  Guaraldi, G ^a   Ventura, P ^a   Albuzza, M ^a   Orlando, G ^a   Bedini, A ^a   Esposito, R ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIRETROVIRUS AGENT; CALCIUM CARBONATE; INDINAVIR; LAMIVUDINE; STAVUDINE; VITAMIN D;

ADULT; CASE REPORT; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; OSTEOPOROSIS; PRIORITY JOURNAL;

ALENDRONATE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 0034923674     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321870     Document Type: Letter

References (3)

1. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
2. Pathologic fractures in patients with osteopenia and osteoporosis induced by antiretroviral therapy
3. Lactic acidemia is associated with spinal osteopenia in HIV-infected men